S

Stryker

Manufactures orthopedic and surgical medical devices

Mechanical Engineer Co-op

InternshipUpdated Deadline 11/3/26
CA$21.39 - CA$30.94/hr
Burnaby, BC, Canada
In PersonWork is mostly in-office at the Burnaby site.
Mechanical EngineeringDesign Engineering

About the job

Requirements
  • Applicants must be enrolled in an engineering program; the posting prefers master's students or students in the third or fourth year of an engineering program, including Mechanical Engineering, Electrical Engineering, Biomedical Engineering, Integrated Engineering, or Biomechanics.
  • Applicants must be available for an eight-month co-op term.
  • Applicants should have hands-on problem-solving skills and be self-managed and self-motivated.
  • Applicants must be fluent with Microsoft Office applications, including Word and Excel.
  • Applicants should have experience with 3D CAD modeling software, preferably SolidWorks.
  • Applicants should have experience with Product Lifecycle Management software, such as Agile PLM or similar.
  • Applicants must be able to write procedures and present complex problems and solutions.
  • Applicants must be able to communicate with groups, review printed materials, and use common office equipment.
  • Applicants must be able to generate and explain design objectives, complete detailed documentation accurately, and troubleshoot designs and provide constructive feedback.
Responsibilities
  • Assist with mechanical design of products in the Stryker Endoscopy portfolio, particularly handheld medical imaging products.
  • Perform design and testing, technical writing, meetings, and quality management system development.
  • Release Engineering Change Orders for Device Master Record documents into Agile Product Lifecycle Management software.
  • Evaluate mechanical design options and conduct bench testing to determine acceptability criteria and optimal solutions within constrained timelines.
  • Provide progress updates in meetings as required.
  • Create test protocols, conduct tests, and generate test reports.
  • Identify and liaise with vendors to support prototyping and new product development.
  • Design and build test fixtures and jigs for verification and product testing as needed.
  • Assist with prototype device assembly, opto-mechanical jig and fixture development, and project manager support as required.
  • Develop quality management system Design History File and Device Master Record documentation for new and existing products, including meetings and cross-functional liaison.
  • Participate in front-end conceptual design and engineering activities for new products.
  • Source components and identify appropriate vendors.
  • Test products and components using early laboratory prototypes and formal product verification testing.
  • Design test setups and testing conditions to investigate options for improving device performance.
  • Work with vendor engineers on system design and perform evaluations and experiments during early design stages.
  • Participate in design reviews, risk management, and associated risk control assessments.
  • Follow proper procedures and best practices, and work with senior engineers to improve them.
  • Contribute to project planning, commit to deliverable goals, and proactively report progress to project and research and development management when required.
  • Take direction from senior engineers and research and development managers, complete most tasks with minimal guidance, and use resources responsibly and effectively.
  • Seek input from senior technical leaders and managers as necessary.
Desired Qualifications
  • Applicants with two to three completed co-op terms are advantageous.
  • Experience with SolidWorks is preferred.

About the company

Stryker makes medical devices for hospitals, surgical centers and emergency responders, spanning joint implants, surgical instruments and patient transport equipment. Its Mako platform assists surgeons with joint replacement, while its neurotechnology products support brain and spine procedures and stroke treatment. Clinicians use its equipment during surgery and emergency care, and the company earns money by selling implants, disposable products and capital equipment through direct sales teams and distributors. The business also supplies training and technical support for healthcare providers using its devices. Stryker was founded in 1941 and is headquartered in Portage, Michigan.

Company Size

10,001+

Company Stage

IPO

Headquarters

Kalamazoo, Michigan

Founded

1941

Get referred to Stryker

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Demand supports growth: July 2026 Stryker results show organic sales rose 9%, with reported sales reaching $6.6 billion.
  • Service extends equipment sales: Stryker's ProCare contracts bundle preventive maintenance, repairs and original manufacturer parts.
  • Relocation is available for Worcester technicians: Stryker's live transport service opening also lists 12 paid holidays.

What critics are saying

  • Operational failures reach customers: March 2026 cyberattack disrupted Stryker's ordering, manufacturing and shipping.
  • Older implants retain legal exposure: Stryker's recall estimates include Rejuvenate, LFIT V40 and legacy Wright hip products.
  • Field service demands travel: Stryker's northern Minnesota opening lists 80% travel plus evening or weekend call.

What makes Stryker unique

  • Mako combines imaging and physical guidance: Stryker uses CT-based planning and haptic boundaries during hip replacement.
  • Discarded devices return to service: Stryker's Sustainability Solutions reprocesses medical equipment for hospitals across the U.S. and Canada.
  • Transport extends its technology outside hospitals: Stryker's Power-LOAD supports stretchers while loading and unloading ambulances.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Medical & prescription plans
  • Supplemental health benefits
  • Flexible Spending accounts
  • Employee Assistance Program
  • Short-term & long-term disability
  • Tuition reimbursement
  • 401(k) plan
  • Employee Stock Purchase Plan

Growth & Insights and Company News

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Oct 30th, 2026
Stryker shares fall 10% as 2026 sales guidance is cut to 6.5%-7.0% growth

Stryker shares fell about 10% to $279.98 before the open on Friday, after the medical device maker missed third-quarter estimates and cut its 2026 sales guidance. The stock was already down about 20% this year. Adjusted earnings per share were $3.52 against $3.55 expected. Revenue was $6.52 billion against $6.62 billion expected, up 7.6%. Stryker now expects 2026 organic sales growth of 6.5% to 7.0%, down from 8.3% to 9.3%. Its adjusted EPS guidance fell to $14.80 to $14.90 from $14.95 to $15.10. Chief executive officer Kevin Lobo said the Mako RPS hip and knee system is "off to a slow start." Spencer Stiles succeeds him and will issue the 2027 guidance early next year.

Yahoo Finance
Oct 29th, 2026
Stryker misses Q3 forecasts with $753M profit on $6.52B revenue

Stryker reported third-quarter profit of $753 million, or $1.96 per share, on Thursday. The Michigan-based medical device maker's adjusted earnings, which exclude asset impairment and amortisation costs, were $3.52 per share. Both results missed Wall Street forecasts. Analysts surveyed by Zacks Investment Research expected earnings of $3.56 per share and revenue of $6.58 billion; Stryker posted revenue of $6.52 billion. The company expects full-year earnings of $14.80 to $14.90 per share.

Associated Press
Oct 29th, 2026
Stryker Q3 sales rise 7.7% to $6.5B, but miss expectations; $3B added to buyback

Stryker reported third-quarter net sales of $6.5 billion, up 7.7% from a year earlier. Organic sales also rose 7.7%, driven mainly by higher unit volume. Reported net earnings fell 12.3% to $753 million, or $1.96 per diluted share, down 11.7%. Adjusted earnings per share rose 10.3% to $3.52, and adjusted operating margin rose 60 basis points to 26.2%. MedSurg and Neurotechnology sales grew 9.2% to $3.7 billion. Orthopaedics sales rose 5.7% to $2.9 billion. Chief executive officer Kevin A. Lobo said the results fell short of expectations, but he expects a solid fourth quarter. Stryker now expects 2026 organic sales growth of 6.5% to 7.0% and adjusted earnings per share of $14.80 to $14.90. It bought back $1.0 billion of stock in the quarter, and its board added $3.0 billion to the repurchase programme.

Yahoo Finance
Oct 28th, 2026
Stryker lags peers with 8.5% growth as plant problems, not hospitals, hit sales

Stryker's stock has lost 20.2% over the past 12 months, dividends included, while the S&P 500 returned 15.0%. Its revenue grew 8.5% over the latest four quarters, slower than four of its five peers, including Boston Scientific (13.5%) and Intuitive Surgical (20.5%). Management says hospital demand is steady. It blames the slowdown on a cybersecurity incident that halted manufacturing and on supply problems in peripheral vascular products. First-quarter fiscal 2026 revenue grew just 2.6%, and operating margin fell to 15.5%. Margin recovered to 25.2% in the second quarter. The stock fell 8.8% on September 8, 2026, after the chief financial officer said the vascular issue was unresolved. Third-quarter results are due October 29, 2026. Spencer Stiles will succeed Kevin Lobo as chief executive officer on January 1, 2027.

Stryker Corporation
Oct 27th, 2026
Stryker Completes Acquisition of MAKO Surgical Corp.

Kalamazoo, Michigan - December 17, 2013 - Stryker Corporation (NYSE:SYK) announced today the completion of its previously announced acquisition of MAKO Surgical Corp., a pioneer in the advancement of robotic arm assisted surgery in orthopaedics. "We're excited to welcome MAKO into our organization and combine their expertise in robotic arm assisted surgery with Stryker's innovations in joint reconstruction to further advance the growth of this compelling technology. The long-term potential offered by this technology platform holds the promise of transforming reconstructive surgery, increasing patient satisfaction and enhancing the experience for surgeons and hospitals," said Kevin A. Lobo, President and Chief Executive Officer. As indicated in the September 25, 2013 press release, the transaction is expected to be dilutive to Stryker's adjusted earnings per share excluding acquisition and integration-related charges by approximately $0.10 - $0.12 in the first full year, neutral in